Five randomized trials have been conducted to prove that shorter duration of trastuzumab treatment (9 weeks or 6 months) can replace the standard duration (1 year). The results of PERSEPHONE, the most recent trial, suggest that the efficacy of a 6-month treatment is non-inferior to that of 1 year, although not for all patients. We discuss these results in the context of current treatment standards.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Romond, E. H. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673–1684 (2005).
Piccart-Gebhart, M. J. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659–1672 (2005).
Slamon, D. et al. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 365, 1273–1283 (2011).
Joensuu, H. et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 354, 809–820 (2006).
Pivot, X. et al. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Lancet 393, 2591–2598 (2019).
Mavroudis, D. et al. Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). Ann. Oncol. 26, 1333–1340 (2015).
Earl, H. M. et al. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet 393, 2599–2612 (2019).
Conte, P. et al. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡. Ann. Oncol. 29, 2328–2333 (2018).
Joensuu, H. et al. Effect of adjuvant trastuzumab for a duration of 9 weeks versus 1 year with concomitant chemotherapy for early human epidermal growth factor receptor-2 positive breast cancer: the SOLD randomized clinical trial. JAMA Oncol. 4, 1199–1206 (2018).
Pondé, N., Gelber, R. D. & Piccart, M. PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer? NPJ Breast Cancer 5, 8 (2019).
von Minckwitz, G. et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N. Engl. J. Med. 380, 617–628 (2019).
Cardoso, F. et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. https://doi.org/10.1093/annonc/mdz173 (2019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
N.P. has received travel grants from Roche–Genentech and has participated in clinical trials sponsored and/or funded by Roche–Genentech. E.d.A. has received research and travel grants and fees from Roche–Genentech and works in an institution that participated in the HERA and APHINITY trials.
Additional information
Related links
ClinicalTrials.gov: https://clinicaltrials.gov
Rights and permissions
About this article
Cite this article
Pondé, N., de Azambuja, E. PERSEPHONE — implications for clinical practice in 2019. Nat Rev Clin Oncol 16, 663–664 (2019). https://doi.org/10.1038/s41571-019-0256-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-019-0256-7
